Monthly Archives: April 2017

http://www.lslog.com/takedas-ariad-deal-pays-off-with-blockbuster-green-light-for-alunbrig/Takeda's Ariad deal pays off with blockbuster green light for Alunbrig

Takeda's Ariad deal pays off with blockbuster green light for Alunbrig

Takeda’s Ariad deal pays off with blockbuster green light for Alunbrig Takeda’s Ariad deal pays off with blockbuster green light for Alunbrig esagonowsky Fri, 04/28/2017 – 13:54 Source: Fierce […]

http://www.lslog.com/novartis-wins-fda-nod-for-rydapt-a-new-targeted-drug-for-acute-myeloid-leukemia/Novartis wins FDA nod for Rydapt, a new targeted drug for acute myeloid leukemia

Novartis wins FDA nod for Rydapt, a new targeted drug for acute myeloid leukemia

Novartis wins FDA nod for Rydapt, a new targeted drug for acute myeloid leukemia Novartis wins FDA nod for Rydapt, a new targeted drug for acute myeloid leukemia epalmer Fri, […]

http://www.lslog.com/medeor-gets-fda-ok-to-trial-therapy-that-aims-to-do-away-with-transplant-drugs/Medeor gets FDA OK to trial therapy that aims to do away with transplant drugs

Medeor gets FDA OK to trial therapy that aims to do away with transplant drugs

Medeor gets FDA OK to trial therapy that aims to do away with transplant drugs Medeor gets FDA OK to trial therapy that aims to do away with transplant drugs […]

http://www.lslog.com/bristol-myers-drops-option-to-buy-her2-cancer-biotech/Bristol-Myers drops option to buy HER2 cancer biotech

Bristol-Myers drops option to buy HER2 cancer biotech

Bristol-Myers drops option to buy HER2 cancer biotech Bristol-Myers drops option to buy HER2 cancer biotech nptaylor Fri, 04/28/2017 – 06:34 Source: FierceMedicalDevices News Bristol-Myers drops option to buy […]

http://www.lslog.com/with-exondys-51-approved-sarepta-chief-ed-kaye-to-bow-out/With Exondys 51 approved, Sarepta chief Ed Kaye to bow out

With Exondys 51 approved, Sarepta chief Ed Kaye to bow out

With Exondys 51 approved, Sarepta chief Ed Kaye to bow out With Exondys 51 approved, Sarepta chief Ed Kaye to bow out badams Fri, 04/28/2017 – 04:17 Source: FierceMedicalDevices […]

http://www.lslog.com/with-fda-nod-biomarin-prices-orphan-drug-brineura-at-702000-but-plans-hefty-discounts/With FDA nod, BioMarin prices orphan drug Brineura at $702,000, but plans hefty discounts

With FDA nod, BioMarin prices orphan drug Brineura at $702,000, but plans hefty discounts

With FDA nod, BioMarin prices orphan drug Brineura at 2,000, but plans hefty discounts With FDA nod, BioMarin prices orphan drug Brineura at $702,000, but plans hefty discounts esagonowsky Thu, […]

http://www.lslog.com/as-supreme-court-steps-into-tangled-biosimilars-law-ip-experts-weigh-in/As Supreme Court steps into tangled biosimilars law, IP experts weigh in

As Supreme Court steps into tangled biosimilars law, IP experts weigh in

As Supreme Court steps into tangled biosimilars law, IP experts weigh in As Supreme Court steps into tangled biosimilars law, IP experts weigh in esagonowsky Thu, 04/27/2017 – 11:01 […]

http://www.lslog.com/rgenix-hires-ex-novartis-cancer-staffer-to-trial-gsk-castoff/Rgenix hires ex-Novartis cancer staffer to trial GSK castoff

Rgenix hires ex-Novartis cancer staffer to trial GSK castoff

Rgenix hires ex-Novartis cancer staffer to trial GSK castoff Rgenix hires ex-Novartis cancer staffer to trial GSK castoff nptaylor Thu, 04/27/2017 – 09:33 Source: FierceMedicalDevices News Rgenix hires ex-Novartis […]

http://www.lslog.com/new-conductor-old-tune-from-u-k-pharma-as-it-threatens-exodus/New conductor, old tune from U.K. pharma as it threatens exodus

New conductor, old tune from U.K. pharma as it threatens exodus

New conductor, old tune from U.K. pharma as it threatens exodus New conductor, old tune from U.K. pharma as it threatens exodus badams Thu, 04/27/2017 – 04:34 Source: FierceMedicalDevices […]

http://www.lslog.com/amgen-sandoz-take-closely-watched-biosimilars-arguments-to-supreme-court/Amgen, Sandoz take closely watched biosimilars arguments to Supreme Court

Amgen, Sandoz take closely watched biosimilars arguments to Supreme Court

Amgen, Sandoz take closely watched biosimilars arguments to Supreme Court Amgen, Sandoz take closely watched biosimilars arguments to Supreme Court esagonowsky Wed, 04/26/2017 – 12:02 Source: Fierce Pharma Amgen, […]